Unit of Research in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID, Rheumatology Research Division, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Grup de Recerca GEMMAIR (AGAUR)-Medicina Aplicada (URV), Departament de Medicina i Cirurgia, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, 43005 Tarragona, Spain.
Nutrients. 2024 May 21;16(11):1545. doi: 10.3390/nu16111545.
Myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and long COVID are complex, multisystemic and long-term disabling conditions characterized by debilitating post-exertional malaise and other core symptoms related to immune dysregulation resultant from post-viral infection, including mitochondrial dysfunction, chronic neuroinflammation and gut dysbiosis. The reported associations between altered microbiota composition and cardinal symptoms of ME/CFS and long COVID suggest that the use of microbial preparations, such as probiotics, by restoring the homeostasis of the brain-immune-gut axis, may help in the management of symptoms in both conditions. Therefore, this review aims to investigate the implications of alerted gut microbiome and assess the evidence supporting use of microbial-based preparations, including probiotics, synbiotics, postbiotics alone and/or in combination with other nutraceuticals in the management of fatigue, inflammation and neuropsychiatric and gastrointestinal symptoms among patients with ME/CFS and long COVID.
肌痛性脑脊髓炎,亦称慢性疲劳综合征(ME/CFS),以及长新冠,均为复杂的、多系统的、长期致残性疾病,其特点是劳累后不适加剧和其他与免疫失调相关的核心症状,这些症状继发于病毒感染后,包括线粒体功能障碍、慢性神经炎症和肠道菌群失调。已报道的微生物组组成改变与 ME/CFS 和长新冠的主要症状之间的关联表明,使用微生物制剂(如益生菌)通过恢复脑-免疫-肠道轴的平衡,可能有助于管理这两种疾病的症状。因此,本综述旨在探讨被激活的肠道微生物组的意义,并评估支持使用微生物制剂(包括益生菌、合生菌、后生元,单独或与其他营养保健品联合使用)来管理 ME/CFS 和长新冠患者的疲劳、炎症以及神经精神和胃肠道症状的证据。